Growth Hormone
HGH 191AA Dosage Protocol
Recombinant 191-amino acid human growth hormone identical to pituitary GH. Complete dosing guide, clinical evidence, and peer-reviewed references.
Last reviewed March 2025 · 2 cited sources
Reconstitution
Add 1.0 mL BAC water → 10 IU/mL
Daily dose range
1–4 IU/day (titrated)
Unit math (U-100 syringe)
1 unit = 0.01 mL ≈ 100 mcg
Storage (lyophilized)
Refrigerate at 2–8 °C (REFRIGERATE -do NOT freeze) · Reconstituted: 36–46 °F · Use within 72 hours
Dosing & Reconstitution Guide
The protocol below uses a 1.0 mL reconstitution volume to keep injection units comfortably above 10 on a standard U-100 insulin syringe, reducing measurement error. Doses are titrated as shown below.
| Phase |
Daily dose |
U-100 units |
Injection volume |
| Low | 1–2 IU/day | 10–20 units | 0.10–0.20 mL |
| Standard | 2–4 IU/day | 20–40 units | 0.20–0.40 mL |
Route: Subcutaneous · Frequency: Daily SC · Cycle: 3–6 months
Reconstitution steps
01
Draw 1.0 mL of bacteriostatic water into a sterile syringe.
02
Inject the water slowly down the interior wall of the peptide vial -never directly onto the powder -to prevent foaming and denaturation.
03
Swirl or roll gently until fully dissolved. Do not shake. The lyophilized powder should dissolve completely within 30–60 seconds.
04
Label the vial with the reconstitution date and concentration (10 IU/mL). Refrigerate at 36–46 °F, protected from light. Use within 72 hours.
Research use only. This protocol is derived from published preclinical and early-phase clinical literature. HGH 191AA is not FDA-approved for human use. This information is not medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before beginning any peptide protocol.
Supplies Needed
Estimates below assume the titration schedule listed above.
HGH 191AA vials (10 IU each)
Per cycleAs needed per titration
U-100 insulin syringes
8 weeks56 syringes
12 weeks84 syringes
16 weeks112 syringes
Bacteriostatic water (10 mL bottles)
Alcohol swabs (100-count boxes)
8 weeks2 boxes (~112 swabs)
12 weeks2 boxes (~168 swabs)
16 weeks3 boxes (~224 swabs)
Storage Instructions
Lyophilized (dry powder)
2–8 °C (REFRIGERATE -do NOT freeze)
Store refrigerated in dry, dark conditions. Do not freeze.
Reconstituted (in solution)
36–46 °F
Refrigerate after reconstitution. Use within 72 hours. Do not refreeze reconstituted solution -freeze-thaw cycles degrade peptide integrity.
Allow refrigerated vials to reach room temperature before opening to minimize condensation uptake. Always inspect for cloudiness or particulates before use -discard if present.
Looking for research-grade peptides? Pacific Edge Labs carries a growing catalog of high-purity compounds with third-party lab results published on each product page.
Why Pacific Edge Labs
- High-purity compounds with third-party lab results available on the website
- Consistent quality control with ISO-aligned handling and documentation
- Fast, discreet shipping with proper handling and packaging
Browse Pacific Edge Labs →
HGH 191AA is not currently in the PEL catalog -check back for availability.
How HGH 191AA Works
HGH 191AA is recombinant human growth hormone containing the identical 191-amino acid sequence produced by the anterior pituitary gland. Unlike GHRH analogs and GH secretagogues that stimulate endogenous GH production through the hypothalamic-pituitary axis, exogenous HGH bypasses this axis entirely, directly activating GH receptors and stimulating hepatic IGF-1 production.[1]
HGH is FDA-approved for adult GH deficiency, Turner syndrome, HIV wasting, and other conditions. It produces the strongest body composition effects (fat loss, lean mass gain) of any GH-axis compound, but at the cost of suppressing endogenous GH production through negative feedback. The Rudman 1990 NEJM trial was landmark in demonstrating lean body mass increases and fat mass reductions in elderly men.[2] Must be REFRIGERATED even as lyophilized powder -only 72 hours stability once reconstituted.
Observed Effects & Side Effect Profile
The following observations are derived from preclinical literature and limited early-phase human data. They do not constitute clinical claims.
Reported benefits (research literature)
- Identical to endogenous pituitary GH -strongest body composition effects
- FDA-approved for multiple GH deficiency indications
- Landmark clinical evidence (Rudman 1990) for lean mass and fat reduction
- Predictable dose-response for IGF-1 elevation
Known limitations & side effects
- Suppresses endogenous GH production through negative feedback
- Must be REFRIGERATED even lyophilized -do NOT freeze; only 72 hours after reconstitution
- Joint pain, carpal tunnel, water retention common at higher doses
- Potential for insulin resistance and glucose intolerance
- Expensive; tightly regulated in most jurisdictions
Lifestyle Considerations
While the following suggestions are not protocol requirements, research on tissue repair and peptide efficacy consistently highlights these as factors that influence outcomes:
01
Protein intake. Collagen synthesis and tissue remodeling require adequate dietary protein. Research generally supports 1.6–2.2 g/kg/day during active recovery periods.
02
Sleep. The majority of tissue repair and growth hormone secretion occurs during deep sleep stages. 7–9 hours of quality sleep per night supports the biological environment in which recovery peptides operate.
03
Activity balance. Avoid complete immobilization (which impedes collagen remodeling) and overuse (which re-injures tissue). Progressive loading appropriate to the injury stage supports functional recovery.
04
Stress management. Elevated cortisol chronically impairs immune function and tissue repair. Evidence-based stress reduction techniques support the recovery environment.
Injection Technique
Standard subcutaneous injection guidance from clinical best-practice references.
01
Wash hands thoroughly. Clean your work surface. Gather all supplies before beginning.
02
Wipe the vial rubber stopper with a fresh alcohol swab. Allow it to dry completely before inserting a needle.
03
Draw the calculated dose volume into a sterile insulin syringe. Invert the syringe and tap to remove air bubbles; expel them before withdrawing the needle from the vial.
04
Select an injection site: abdomen (at least 2 inches from the navel), outer thigh, or upper outer arm. Clean with a fresh alcohol swab and allow to dry.
05
Pinch a fold of skin between thumb and forefinger. Insert the needle at a 45–90° angle depending on body fat thickness -45° for leaner individuals, 90° for more subcutaneous tissue.
06
Do not aspirate. Current clinical guidelines do not recommend aspiration for subcutaneous injections. Inject slowly and steadily over 2–3 seconds.
07
Wait 3–5 seconds after the plunger bottoms out before withdrawing the needle at the same angle. Apply gentle pressure with a clean swab -do not rub vigorously.
08
Rotate injection sites systematically with every dose. Reusing the same site repeatedly causes lipohypertrophy (hardened fat tissue) which reduces absorption consistency.
09
Dispose of used needles and syringes immediately in a puncture-resistant sharps container. Never recap needles by hand.
Important Notes
⚠
Research use only. HGH 191AA is not FDA-approved for human use. Human clinical data may be limited. Do not use without consulting a qualified healthcare professional.
◎
One syringe per injection. Never reuse needles or syringes. Each injection requires a fresh, sterile syringe to prevent contamination and infection risk.
⚠
REFRIGERATE even lyophilized -do NOT freeze
⚠
Only 72 HOURS stability once reconstituted
⚠
Suppresses endogenous GH production
◎
Document your protocol. Record daily dose, injection site, and any observations. This supports consistency and allows you to identify patterns or issues over the course of the cycle.
◎
Inspect before each use. The reconstituted solution should be clear and colorless. Discard if cloudy, discolored, or if particulates are visible.
References
All dosing recommendations and mechanism descriptions on this page are derived from the following peer-reviewed publications and regulatory documents.
1
PubMed 10352397
Kim KR et al. Low-dose growth hormone treatment with diet restriction accelerates body fat loss and improves growth hormone secretory dysfunction in obese adults
pubmed.ncbi.nlm.nih.gov/10352397 ↗
